JP2024511281A5 - - Google Patents

Info

Publication number
JP2024511281A5
JP2024511281A5 JP2023550307A JP2023550307A JP2024511281A5 JP 2024511281 A5 JP2024511281 A5 JP 2024511281A5 JP 2023550307 A JP2023550307 A JP 2023550307A JP 2023550307 A JP2023550307 A JP 2023550307A JP 2024511281 A5 JP2024511281 A5 JP 2024511281A5
Authority
JP
Japan
Prior art keywords
sequence
seq
chain variable
variable region
antibody conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511281A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/076810 external-priority patent/WO2022174809A1/en
Publication of JP2024511281A publication Critical patent/JP2024511281A/ja
Publication of JP2024511281A5 publication Critical patent/JP2024511281A5/ja
Pending legal-status Critical Current

Links

JP2023550307A 2021-02-19 2022-02-18 抗ｃｌｄｎ１８．２抗体コンジュゲート Pending JP2024511281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076910 2021-02-19
CN2021076910 2021-02-19
CN2022074750 2022-01-28
CNPCT/CN2022/074750 2022-01-28
PCT/CN2022/076810 WO2022174809A1 (en) 2021-02-19 2022-02-18 Anti-cldn18.2 antibody conjugates

Publications (2)

Publication Number Publication Date
JP2024511281A JP2024511281A (ja) 2024-03-13
JP2024511281A5 true JP2024511281A5 (https=) 2025-02-27

Family

ID=82932096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550307A Pending JP2024511281A (ja) 2021-02-19 2022-02-18 抗ｃｌｄｎ１８．２抗体コンジュゲート

Country Status (9)

Country Link
US (1) US20240307564A1 (https=)
EP (1) EP4294441A4 (https=)
JP (1) JP2024511281A (https=)
KR (1) KR20230146623A (https=)
CN (1) CN117460528A (https=)
AU (1) AU2022223150A1 (https=)
CA (1) CA3211403A1 (https=)
TW (1) TW202302153A (https=)
WO (1) WO2022174809A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041574A1 (en) * 2022-08-24 2024-02-29 Suzhou Transcenta Therapeutics Co., Ltd. Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
KR20240176948A (ko) * 2023-06-15 2024-12-26 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
KR20250062080A (ko) 2023-10-30 2025-05-08 주식회사 엘지에너지솔루션 배터리 데이터 수집 서버 및 이의 동작 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2852409B1 (en) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3765522A4 (en) * 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020025792A1 (en) * 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN114206935B (zh) * 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 新型cldn18.2结合分子
JP7767270B2 (ja) * 2019-08-20 2025-11-11 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｃｌｄｎ１８．２抗体
CN111777681B (zh) * 2020-07-06 2022-10-11 康诺亚生物医药科技（成都）有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途

Similar Documents

Publication Publication Date Title
CA2489467C (en) Humanized monoclonal antibody hpam4
JP2024511281A5 (https=)
AU2019234468B2 (en) Bispecific binding agents and uses thereof
Oriuchi et al. Current status of cancer therapy with radiolabeled monoclonal antibody
CN110799542A (zh) 抗-b7h3抗体用于治疗中枢神经系统癌症的用途
US20120034158A1 (en) Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis corresponding compositions and kits
CA2489469A1 (en) Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
JP7836270B2 (ja) 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物
US20240307564A1 (en) Anti-cldn18.2 antibody conjugates
WO2024041574A1 (en) Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
CA2665957A1 (en) Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
Goldenberg et al. Radioactive antibodies: a historical review of selective targeting and treatment of cancer
CA3208566A1 (en) Antibodies to igf2r and methods
Khandave et al. Radioligand–Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis
WO2012032043A1 (en) 212 pb imaging
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物
Arev et al. Radioimmunoconjugates of various monoclonal antibodies as potential anticancer therapy-review
Prasad et al. Radioimmunotherapy
Stoldt et al. G. Paganelli, M. Chinol
Sharkey et al. Pretargeted radioimmunotherapy of cancer
BREITZ¹ et al. NeoRx-Virginia Mason Clinical Research Unit, Seattle, WA, 2Virginia Mason Medical Center, Seattle, WA, 3NeoRx Corporation, Seattle, WA
Perk et al. Immuno-Positron Emission
Chopra 111 In-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N’, N”, N”’-tetraacetic acid (DOTA)-D-Tyr-D-Lys (HSG)-D-Glu-D-Lys (HSG)-NH2 (IMP-288)[[111 In]-IMP-288],”
Goldenberg et al. Antibodies for Nuclear Medicine Therapy
IL165752A (en) Chimeric monoclonal antibody pam4, a conjugate comprising it and an antibody comprising the same or fragments thereof